Relay Therapeutics Profit Margin

The latest profit margin for RLAY is -2554.37% as of March 2026. That compares with -4341.53% in the prior-year period — up 41.2% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside Relay Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, RLAY's profit margin moved from -4341.53% to -2554.37% — a 41.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Relay Therapeutics's valuation or profitability profile.

Against Healthcare companies, RLAY currently prints -2554.37% for profit margin, while the sector average sits near 15.58%. That is roughly 16491.0% below the sector mean. Large gaps often invite a closer look at Relay Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Relay Therapeutics converts resources into returns. At -2554.37%, RLAY may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -4341.53% in the prior-year period — up 41.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RLAY's profit margin (-2554.37%), review year-over-year change from -4341.53%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.